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Abstract
Cell adhesion and migration depend on engagement of extracellular matrix ligands by integrins. Integrin activation is
dynamically regulated by interactions of various cytoplasmic proteins, such as filamin and integrin activators, talin and
kindlin, with the cytoplasmic tail of the integrin b subunit. Although filamin has been suggested to be an inhibitor of
integrin activation, direct functional evidence for the inhibitory role of filamin is limited. Migfilin, a filamin-binding protein
enriched at cell-cell and cell-extracellular matrix contact sites, can displace filamin from b1 and b3 integrins and promote
integrin activation. However, its role in activation and functions of different b integrins in human vascular cells is unknown.
In this study, using flow cytometry, we demonstrate that filamin inhibits b1 and aIIbb3 integrin activation, and migfilin can
overcome its inhibitory effect. Migfilin protein is widely expressed in different adherent and circulating blood cells and can
regulate integrin activation in naturally-occurring vascular cells, endothelial cells and neutrophils. Migfilin can activate b1, b2
and b3 integrins and promote integrin mediated responses while migfilin depletion impairs the spreading and migration of
endothelial cells. Thus, filamin can act broadly as an inhibitor and migfilin is a promoter of integrin activation.
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Introduction
During homeostatic processes, such as hemostasis, angiogenesis
and inflammation, cells must respond with immediacy and
precision to different physiological and pathological cues. The
orchestration of cellular responses often depends upon remodeling
of the actin cytoskeleton which is tightly regulated by a protein
circuitry that connects the intracellular milieu to the extracellular
environment. Integrin heterodimeric adhesion receptors play
important roles in this bidirectional communication between cells
and their environment by engaging extracellular ligands via their
extracellular regions and interacting with different cytoskeletal
proteins via their cytoplasmic tails (CTs). Mechanistically, the
ability of integrins to transit between high and low affinity states
for extracellular ligands, inside-out signaling, provides a means to
dynamically regulate cellular responses. Such regulation of
integrin activation is initiated by their interactions with different
intracellular adaptor proteins.
Filamin (FLN), a 280 kDa protein that is characterized by an N-
terminal actin binding domain followed by 24 Ig-like repeats, helps
to organize actin into an orthogonal network. The filamin repeats
allow the entire protein to act as a hub for interaction with a wide
variety of proteins. There are three isoforms of FLN; FLNA and B
have ubiquitous expression while FLNC is restricted to cardiac
and skeletal muscle. Several studies have implicated FLN repeat
21 as an integrin binding motif [1–5], but a recent study has
shown that integrin b CT can bind to other FLN repeats as well
[5]. Binding of FLN to b integrin CT inhibited integrin mediated
migration in a model cell system [6] while another cytoskeletal
protein, talin, also binds to integrin b CT and activates integrins
[7]. Talin and FLN binding sites in integrin b CT overlap and
competition between these two proteins may play a significant role
in regulating the activation states of integrins [1] and inhibiting
talin mediated outside-in signaling [8]. However, direct evidence
that FLN influences integrin activation (inside-out signaling)
directly remains limited.
Migfilin is a protein found in cell-cell and cell-ECM connections
where it co-localizes with FLNA/C [9] and FLNB [10]. Indeed,
migfilin was found to bind directly to FLNA/C and to be an
important regulator of cell shape and motility [9]. Migfilin consists
of three domains: the N-terminal (residues 1–85), the proline rich-
region (residues 85–176) and C-terminal LIM domains (residues
176–373). Migfilin exerts its influence on cellular functions by
interacting with various binding partners; FLN via its N- terminal
domain [3,4,9], VASP [11] and Src [12] via its proline-rich region,
and kindlin-2 [9] and the cardiac transcription factor, CSX/
NKX2-5 via its C-terminal LIM domains [13]. Among these,
kindlin-2 has been shown to enhance the b3 integrin activating
function of talin [14,15]. Migfilin can be expressed as three
different splice variants. Isoform A (full length) has a theoretical
molecular mass of 40.6 kDa, isoform B, referred to as FBLP-1, is
40.3 kDa and isoform C, migfilin(s), which lacks the proline rich
region, is 30.7 kDa. However, using two different migfilin
antibodies, the major isoform has mobility on SDS-PAGE that
predicts a molecular weight of 50 kDa.
Most studies on integrin activation mechanisms focus on
proteins that bind directly to b cytoplasmic tails (CT) (e.g. talin,
FLN, kindlin). Compared to talin and kindlins that activate
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activation have received less attention. Recent NMR and X-ray
crystallographic data elucidated the structure of the migfilin-FLN
complex [3,4], and indicated that the binding site of migfilin on
FLNA/C overlaps with that of integrin b7 and b2 CT. Since
migfilin bound FLN with a higher affinity, it could uncouple the
FLN-integrin link and promote integrin activation. Support for
this displacement model was derived from NMR and cell-based assays
in which constructs leading to migfilin over-expression or cell-
permeable migfilin peptides containing the FLN binding site,
activated integrins [4]. Since the binding region on FLN repeat 21
of b integrin CTs is conserved, the broad prediction of displacement
model is that FLN would be an inhibitor and migfilin a promoter of
integrin activation. To further test and generalize this prediction,
we measured and manipulated migfilin levels in various naturally-
occurring cells and determined its effects on the activation of b1,
b2 and b3 integrins and then sought mechanistic insights into the
observed effects by altering FLN and migfilin levels in a
combinatorial fashion in various cellular backgrounds. Our
present study establishes FLN as a negative regulator of integrin
inside-out signaling, and provides a mechanism via migfilin of how
such inhibition could be relieved from b integrins to facilitate their
activation for cellular processes.
Methods
Plasmid constructs
The GFP-tagged migfilin construct has been described
previously [4]. The N-terminal region (residues 1–85; Nter) of
migfilin was cloned into the EGFP-N1 vector and an N-terminal
mutant (NterMT) was generated by mutating S
11S
12V
13 in the
FLN- binding sequence of migfilin to D
11D
12A
13. EGFP-tagged
full length FLNA was a generous gift from Dr. Fumihiko
Nakamura, Harvard Medical School. Truncated FLNA constructs
in DsRed Hyg-N1 vector were also generated. Human wild type
aIIb and b3 integrin cDNA was in pcDNA3.1 (+) vector. The
Quik-Change II XL site directed mutagenesis kit from Stratagene
was used to generate all constructs. All constructs were confirmed
by sequencing.
Antibodies and other reagents
Mouse monoclonal migfilin antibody was from Genetex,
HUTS-4 from Millipore, PAC1 and FITC-PAC1 from BD
Biosciences, goat anti-mouse Alexa Fluor 647 IgG, Alexa Fluor
633 IgM, Alexa 647 labeled human fibrinogen, UV-excitable
LIVE DEAD dye from Molecular Probes and human recombi-
nant vascular endothelial growth factor (VEGF) was from R&D
Systems. b-actin antibody, DMSO were from Sigma Chem. Co.
Mouse monoclonal antibody, 2G12 to detect aIIbb3 integrin
expression has been described [16]. PE-CD11b antibody and
associated PE isotype control were from eBioscience. CD66b
antibody was from Abcam. iC3b was from Calbiochem and fMLP
peptide was from Fluka Analytical.
Peptide synthesis
Cell permeable migfilin peptides directly linked to nine arginines
(R9) at their C-terminus were synthesized in the Biotechnology
Core of the Cleveland Clinic. Peptides were purified by reverse
phase HPLC, and their masses confirmed by mass spectrometry.
Completely lyophilized samples were weighed and dissolved in
Tyrode’s buffer (with 0.1% glucose but without divalent ions,
pH 7.4).
15N labeled FLNA repeat 21 was purified as reported
previously [4], and binding to integrin b1 CT peptide (WDTGEN-
PIYKSAVTTVVNPKYEGK) was performed in a Bruker Advance
600 MHz NMR spectrometer equipped with a cryoprobe in 2D
1
H-
15N HSQC experiments. The sequence of the WTMigfilinR9
peptide is: MASKPEKRVASSVFITLAPPRRDVRRRRRRRRR
and that of the MTMigfilinR9 peptide: MASKPEKRVADSAFI-
TLAPPRRDVRRRRRRRRR (mutated residues underlined & in
bold).
Cell culture
FLNA
2 (M2) or FLNA
+ melanoma (A7) cells from ATCC were
grown in 16 a-MEM with 10 mM HEPES, 10% fetal bovine
serum (FBS) and 1% penicillin-streptomycin with the A7 media
using 0.5 mg/ml G418 [17] for selection. CHO cells were
cultured in DMEM: F-12 with 10% FBS and 1% penicillin-
streptomycin. HL60 cells [18] from ATCC were cultured in
Iscove’s modified Dubelco’s medium with 10% FBS and 1%
penicillin-streptomycin. HL60 cells were differentiated into the
granulocytic pathway by 1.3% dimethylsulfoxide treatment for 6
days [19,20]. Human umbilical vein endothelial cells (HUVECs)
from single donors were kindly provided by Dr. Paul DiCorleto,
Cleveland Clinic, and cultured in complete MCDB105 media
containing endothelial growth supplement (BD Biosciences),
heparin (Sigma), 15% FBS and 1% penicillin-streptomycin as
described [21]. Bovine aortic endothelial cells (BAEC) were grown
in DMEM with 10% FBS and 1% penicillin-streptomycin.
Isolation of platelets and neutrophils
Blood was obtained from healthy volunteers under written
informed consent. The blood drawing protocol and the consent
form were approved by the Institutional Review Board of the
Cleveland Clinic (in May 2010 and reapproved May 2011).
Platelets were isolated as in [4] while neutrophils were isolated as
described in [22].
Transfections
Lipofectamine 2000 was used with 2 mg of pEGFP-N1 vector
control or migfilin in pEGFP-N1 vector per well of 6-well tissue
culture plates containing A7, M2 or BAEC cells grown to 95%
confluence. After 4 hours, the media were replaced with antibiotic-
free media and assayed for specific functions after 24 hours. HL60
or differentiated HL60 cells (dHL60) were transfected with similar
amounts of DNA using a HL60-specific nucleofection kit (Lonza)
andassayedforintegrinexpressionandactivation asfortheA7cells.
For aIIbb3 integrin transfections, 5 mge a c ho fW TaIIb with 5 mg
of WT b3 were used along with different protein constructs and
processed 48 hours post-transfection or nucleofection. For all cell
types (except HL60 & dHL60), cells were detached with EDTA
buffer as described [4]. HL60 & dHL60 cells, which grew in
suspension, were centrifuged and resulting cell pellet was resus-
pended in the selected assay buffer.
RNA interference
For migfilin knockdown in HUVECs, 50 nM of negative control
siRNA (Ambion) or On-Target smart pool migfilin siRNA (Dhar-
macon) were transfected using Targefect F-2 and peptide enhancer
(Targeting Systems, CA) as described in [23]. The target sequences
of the siRNAs in the SMARTpool are: (i) UGUACUGCCUG-
GACGACUU, (ii) CCAUGAAGAGGCAGUACCA, (iii) GCAU-
UGGGGAUGAGAGCUU, and (iv) GAAGAGGGUGGCAUC-
GUCU. Cells were harvested 48 hrs after transfection, and Western
blotting was done to measure the extent of migfilin knockdown. For
cell spreading assays, 50 nM of siGLO RISC-free control siRNA
(Dharmacon) was co-transfected to track cells containing migfilin
siRNA [24].
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Differentiation of HL60 cells into a granulocytic phenotype,
dHL60 cells, was confirmed with flow cytometry (FACS) using
phycoerythrin-conjugated CD11b [25] or CD66b [26] antibody,
and phycoerythrin-isotype antibody or Alexa Fluor 647 tagged
secondary antibody were used as background controls. All FACS
data were acquired on a BD LSRII instrument and analyzed using
FlowJo7.6.3 software (Treestar). Median fluorescence intensities
were calculated and presented as relative fluorescence units (RFI).
Binding of activation-specific antibodies or ligands are expressed
as fold change over vector or unstimulated controls, taken as 1.
Integrin activation assays
b1 (M2, A7, BAEC, HUVEC) and aIIbb3 (platelets, M2 cells &
K562 cells stably expressing aIIbb3 integrin) integrin activation
assays were performed as previously described [4] using HUTS-4
and PAC-1 antibodies, respectively. Expression of aIIbb3 integrin
was monitored by 2G12 antibody [16] in transient over-expression
experiments. Data from co-transfection experiments with transient
expression of WT aIIbb3 integrin have been optimized for surface
expression of exogenous integrins. For these experiments, cells
were processed for flow cytometry, 48 hours post-transfection.
The activation-specific monoclonal antibodies, CBRM1/5
(eBioscience) for activated aM subunit [27] and mAb24 (Cell
Sciences) for activated aL, aM aX subunits of b2 integrins [28]
were used to measure the activation status of b2 integrins in HL60,
dHL60 cells and neutrophils as described [22]. Briefly, HL60 or
dHL60 cells expressing empty vector or migfilin, or neutrophils
treated with migfilin WT and MT peptides were incubated with
10 mg/ml of Alexa Fluor 647 conjugated CBRM1/5 antibody or
an isotype control for 30 min at 37uC. For mAb24 antibody,
10 mg/ml was used with Alexa Fluor 647 conjugated secondary
antibody. In all assays, the buffer was Hank’s Balanced Salt
Solution with Ca
2+,M g
2+ and 0.1% BSA, except for mAb24 assay
where only Mg
2+ was used in the buffer [28]. Soluble fibrinogen
binding using Alexa Fluor 647 labeled fibrinogen (Molecular
Probes) was performed to monitor aVb3 integrin activation in
BAECs. As positive control for integrin activation, 10 mM TRAP6
(platelets), 3.5 mM MnCl2 (M2, HL60, HUVECs, BAECs) or
8 nM PMA (neutrophils) were used. All peptide or agonist (positive
control) treatments were done for 5 minutes at 37uC in a tissue
culture incubator. All flow cytometric data were acquired and
analyzed as explained above.
Adhesion, spreading and migration assays
Lab-tek slides (Nunc) were coated with saturating concentration
of iC3b overnight at 4uC, blocked with 0.2% gelatin at 37uC for
2 hrs, washed with PBS and vector or migfilin over-expressing
HL60 or dHL60 cells (total 10,000 cells/well) were allowed to
adhere for 30 min at 37uC, 24 hours after nucleofection. Slides
were gently washed with PBS, fixed with 4% paraformaldehyde
and then washed with PBS. Slides were mounted with Vectashield
with DAPI (Vector Laboratories, CA), and pictures taken under a
Leica epifluorescence microscope using a 406 oil objective.
Adherent cells are expressed as a proportion of GFP
+ to DAPI-
stained cells for each treatment.
For HUVEC spreading assays, ,10,000 cells/cover slip were
plated on coverslips coated with 15 mg/ml fibronectin, as a b1
integrin ligand, or 20 mg/ml fibrinogen as a b3 integrin ligand.
Prior to experiments, the ligand-coated coverslips were blocked
with 0.1% BSA at 37uC for 2 hours and washed with PBS. Cell
spreading was monitored at 30 and 60 min, after which the slides
were washed, fixed with 4% paraformaldehyde and permeabilized
with 0.2% TritonX-100. Subsequently, actin was stained with
Alexa Fluor 488 conjugated phalloidin for 30 min at room
temperature, washed and coverslips mounted with Vectashield
with DAPI and photographs taken. For each treatment, the area of
at least 100 cells was measured using the ImageJ software (NIH).
For migration assays, the undersides of 8 mm pore filters of
transwells (Costar) were coated with fibronectin or fibrinogen as
for cell spreading assays. HUVECs were transfected with siRNA
and after 24 hrs washed and kept overnight at 37uC in starvation
medium (non-COMPLETE HUVEC medium with 0.5% FBS).
After dissociation, cells were resuspended in non-COMPLETE
HUVEC media with 0.1% BSA, and added to the upper chamber
of the transwells. Cells were induced to migrate by adding 15 mg/
ml (for fibronectin coated filters) or 20 mg/ml (fibrinogen coated
filters) recombinant VEGF to non-COMPLETE HUVEC media
with 0.1% BSA, in the lower chamber of the transwells. After 8 hrs
of migration at 37uC in a 5% CO2 containing humidified
incubator, the non-migrated cells from the upper chamber were
removed, and the cells on the underside of the filter fixed with
70% methanol and stained with 1% toluidene blue. Cells
migrating across the integrin ligands were quantified from
microscopic pictures taken from 3 random fields.
Results
Migfilin in endothelial cells and circulating blood cells
Although migfilin has been detected in many different tissues
[10,13], its presence in specific cell types has not been established.
To provide insight into the cellular distribution of migfilin, lysates
of selected cell types were immunoblotted with a migfilin antibody
that can detect the various splice variants of migfilin. Endothelial
cells from both veins (HUVEC) and arteries (BAEC) contained
migfilin protein. In addition, circulating human blood cells,
platelets, neutrophils and monocytes, also contained migfilin
(Fig. 1A). We focused on the band of migfilin corresponding to
50 kDa (major isoform) to compare levels between various cell
types. Of the cells tested, migfilin was more abundant in the
adherent cells, HUVEC and BAEC, than in the blood cells and
was particularly prominent in HUVEC. Despite the vast
differences in FLN levels, M2 (lack FLNA but express FLNB)
and A7 (have both FLNA and FLNB) cells have similar migfilin
levels. The migfilin levels in the blood cells were lower than in
adherent cells tested, and both migfilin and a band consistent with
the FBLP-1 isoform were detected in these cells. When expression
of the major migfilin isoform was normalized to actin levels in the
different cell lysates and HUVEC migfilin levels assigned a value
as 100%, neutrophils and monocytes contained 30% and 40%,
respectively, of the migfilin levels in HUVECs. Platelets had the
least migfilin of the cells tested, ,15% of that present in HUVEC
(Fig. 1B). In our subsequent studies, we focused on HUVECs as a
high migfilin expresser and a cell where adhesion and migration
responses are functionally important and on neutrophil-related
cells, where migfilin is expressed at lower levels but where integrin
activation is integral to their biological responses.
Role of migfilin in activation of b1, b2&b3 integrins
To investigate the role of migfilin in integrin activation of
different b integrins, two independent strategies were adopted: (i)
transient over-expression of migfilin in endothelial cells and
granulocytic cells, and (ii) cell-permeable synthetic migfilin
peptides that block FLN-integrin interaction in endothelial cells,
neutrophils and platelets.
Effect of migfilin over-expression on integrin activation: For these
experiments, BAECs were used since these cells are more readily
transfectable than HUVECs. Migfilin expression in BAECs
Migfilin, Filamin and Integrin Activation
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with respect to vector as monitored with HUTS-4 antibody
(Fig. 2A). When b3 integrin activation was monitored in these cells
(Fig. 2B), migfilin over-expression resulted in a 2-fold increase of
soluble fibrinogen binding compared to vector control (p,0.05).
Thus, migfilin expression enhanced both b1 and b3 integrin
activation in endothelial cells.
HL60 cells were used to study the effect of migfilin on b2
integrin activation. As reported [29], aMb2 is upregulated when
HL60 cells are differentiated into a granulocytic phenotype,
Figure 1. Migfilin expression in different human vascular cells. (A) Immunoblots showing migfilin in whole cell lysates of different circulating
and non-circulating cell types. Migfilin immunoblots reflect signals after 5 min of exposure while the actin bands were exposed for ,2 seconds on
the X-ray film. (B) The intensities of the 50 kDa migfilin band were quantified by densitometry and normalized to actin band intensities in the same
gels.
doi:10.1371/journal.pone.0026355.g001
Figure 2. Migfilin activates b1, b2&b3 integrins in bovine aortic endothelial (BAE) and model granulocytic cells. Compared to vector
control, migfilin induces 2–5 fold increase in b1 and b3 integrin activation in BAEC as monitored by HUTS-4 binding (A) and Alexa Fluor 647-labeled
fibrinogen binding (B), respectively. (C–F) HL60 cells were differentiated for 6 days with DMSO and processed for flow cytometry as described in
Methods. Transfection of the undifferentiated HL60 cells (C, E) did not significantly affect activation of the b2 integrins compared to the vector, as
monitored by the b2 activation-specific antibodies, CBRM1/5 or mAb24. In contrast, transfection of the dHL60 cells with migfilin caused a .2.5 fold
increase (p,0.05) in binding of these antibodies compared to vector control (D, F). Data are representative of 3 independent experiments. Values are
means6 S.E. ** denotes p,0.01 and * denotes p,0.05. In all experiments, Mn
2+ was used as a positive control for integrin activation assay.
doi:10.1371/journal.pone.0026355.g002
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aMb2 expression in the dHL60 cells on day 6 after DMSO
treatment as well as a 21% increase in CD66b expression, a
marker for granulocytic differentiation [26,30].The influence of
migfilin on the activation status of b2 integrins in the dHL60 cells
was first assessed by an over-expression approach. We monitored
activation of aM subunit within aMb2 as a representative b2
integrin using CBRM1/5, a mAb that reacts selectively with
residues on the I-domain near the ligand binding site [31] and
mAb24, a mAb that reacts with a ligand-induced binding site on
the aL, aM and aX subunits of b2 integrins in a Mg
2+-dependent
manner [28]. With both reporter mAbs, the dHL60 cells
transfected with migfilin gave a significantly higher binding
compared to the vector control (p,0.05) with migfilin inducing
a 2.7 fold increase in CBRM1/5 and a 3.5 fold increase in mAb24
reactivity, respectively (Fig. 2D, F). In undifferentiated cells,
migfilin expression induced activation that was not significantly
different from the vector control reflecting the low aMb2
expression on the undifferentiated cells (Fig. 2C, E).
Integrin activation by migfilin peptides: In prior studies [4], we utilized
a wild-type (WT) peptide corresponding to residues
4K to-P
19 of
migfilin which harbor the FLN binding sequence and a mutant
(MT) peptide which contained 2 point mutations that substantially
reduced but did not totally eliminate, FLN binding. Previously,
these peptides had been cys-coupled to an N-terminal disulfide
linked CR7-tag for cellular uptake. In the present study, for ease of
synthesis, we used a string of 9 arginines, R9, rather than a CR7
tag, for cell permeability as widely used in literature [32,33]. In our
previously described approaches of flow cytometry and confocal
microscopy [34], uptake of the arginine-tagged peptides was
confirmed because untagged peptides were unable to enter the
cells.
Using NMR experiments, we observed that b1C Tp e p t i d e
causes substantial shifts upon interaction with FLNA repeat 21.
Furthermore, by NMR, we confirmed binding of R9 conjugated
migfilin peptides to FLN repeat 21 and found that the spectral
shifts were very similar to the CR7 conjugated migfilin cell
permeable peptides and, that the R9 conjugated peptide induced
significant (p,0.05) activation of integrin aIIbb3 in platelets as
measured with the activation specific mAb PAC1 as compared to
the MT peptide (Fig. S1) and platelet aggregation (not shown).
The differential in the PAC-1 binding induced by the WT and
MT peptide was greater at 50 mMc o m p a r e dt o1 0mM, and this
concentration was used to test the effects of the peptides on
activation of integrins in HUVECs and circulating blood cells. As
shown in Fig. 3A, WT peptide induced significantly higher
(p,0.05) activation of b1 integrins than the MT peptide in
HUVECs as measured by binding of the b1 activation specific
mAb, HUTS-4. Blockade of aVb3 integrin by LM609 antibody
prevented fibrinogen binding of HUVECs treated with migfilin
peptides (data not shown) further confirming that migfilin
peptides target integrin activation. Thus, the WT migfilin peptide
induced substantial activation of both b1a n db3 integrins in
HUVEC.
To extend these observations to the b2 integrins in blood
neutrophils, we treated human neutrophils with these cell
permeable migfilin peptides. As shown in Fig. 3B, the WT peptide
induced a response as high as PMA (positive control). The effect of
the WT migfilin peptide on aMb2 activation was also significantly
higher (p,0.05) than the MT migfilin peptide. Translocation of
aMb2 from an internal pool to the cell surface occurs when
neutrophils are activated with inflammatory stimuli [35], but
50 mM WT migfilin peptide induced only a modest (34% increase)
in aM surface expression as assessed by FACS (data not shown).
Thus, the measured increase in CBRM1/5 binding (2-fold with
respect to resting neutrophils) induced by the peptide is due
primarily to activation of cell-surface aMb2 and not due to its
translocation to the cell surface. The high affinity of migfilin to
FLN [5,34,36] makes it difficult to construct a mutant migfilin
peptide that will completely abolish FLN-binding, but the mutant
migfilin peptide was still substantially less potent in inducing aMb2
activation than the WT peptide (Fig. 3B).
Role of migfilin in b1, b2&b3 integrin-mediated
responses
siRNA was used to reduce endogenous migfilin expression in
HUVEC. As assessed by Western blots of cell extracts collected
48 hr after transfection with either migfilin siRNA or control
siRNA, the migfilin protein levels were significantly reduced by the
migfilin siRNA (Fig. 4A). Densitometric scans of the gels and
normalization to the actin loading control estimated the
reduction by the migfilin siRNA to be .70%. We then measured
two integrin dependent responses, spreading and migration, in
the HUVEC treated with the migfilin siRNA or the control
siRNA. Migfilin knockdown resulted in a significant (p,0.01)
reduction in spreading of HUVECs on fibronectin, an interaction
Figure 3. Integrin activation of b1 and b2 integrins with MT and
WT migfilin peptides. (A) HUVECS or (B) human neutrophils were
treated with 50 mM wild type (WT) and mutant (MT) migfilin peptides
for 5 min at 37uC. Using flow cytometry, HUTS-4 binding or CBRM1/5
binding was then measured to evaluate the extent of b1o rb2 integrin
activation, respectively. Data are representative of 3 independent
experiments. Values are means6 S.E * denotes p,0.05. As a positive
control Mn
2+ was again used for b1 integrin activation assay.
doi:10.1371/journal.pone.0026355.g003
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the cells. This effect was obvious at 30 min and was still apparent
1 hour after spreading on the substratum (Fig. 4B). On
fibrinogen, a aVb3 ligand, the area of cells depleted in migfilin
was also significantly smaller (p,0.01) than that of control siRNA
treated HUVEC at the 30 min time point. Although these cells
did spread with time, even at 1 hr, they failed to reach the levels
of spreading observed with HUVECs treated with control siRNA
(p,0.05) (Fig. 4C).
To assess the effects of migfilin knockdown on HUVEC
migration, the siRNA treated cells were placed in a modified
Boyden chamber and allowed to migrate across either fibronectin
or fibrinogen toward VEGF. In this assay, only 30% of the migfilin
siRNA HUVECs migrated towards the stimulus compared to
control siRNA treated HUVEC. This profound difference in
migration was observed on both fibronectin and fibrinogen
substrates (Fig. 4D). Thus, the absence of migfilin in endothelial
cells severely compromises their ability to modulate their
morphology and migrate in response to a chemotactic gradient,
two crucial responses of endothelial cells.
To evaluate the functional relevance of migfilin induced b2
integrin activation, adhesion of differentiated HL60 cells to iC3b,
a ligand for aMb2 and aXb2 involved in microbial clearance
during infection and inflammation [37,38,39], was monitored.
Migfilin transfected dHL60 cells exhibited significantly higher
adhesion (p,0.05) to iC3b compared to vector control and the
extent of adhesion was similar to that induced by Mn
2+ ,a n
inducer of integrin activation (Fig. 5).
Filamin as an inhibitor of integrin activation
Although it is clear that FLN influences integrin dependent
responses of cells, such as spreading and migration [2,6,8], its
specific roles in integrin inside-out signaling (integrin activation), as
distinguished from outside-in signaling, is less well demarcated.
Thus, we sought to demonstrate the inhibition of integrin
activation by FLN and the ability of migfilin to overcome this
inhibition, key predictions of the displacement model. For FLN
expression, we used either a vector encoding for full length FLNA,
or, to overcome low expression of intact FLN in co-expression
systems, one encoding a form composed of repeats 16–24, which
contains four integrin binding sites in alternate repeats [5]. The
full-length FLNA construct was expressed in CHO cells, where
activation of endogeneous b1 integrin was monitored, or in M2
cells transiently expressing aIIbb3 to determine effects on
activation of a b3 integrin. Both full-length FLNA (p,0.05) and
a single repeat of FLNA, repeat 21 (p,0.001) significantly
inhibited the extent of b1 integrin activation in these cells as
monitored with the b1-activation specific mAb HUTS-4, com-
pared to vector control. Under the same conditions, talin head and
migfilin both significantly activated the b1 integrins compared to
the vector (Fig. 6A). Over-expression of full length FLNA also
inhibited b3 integrin activation in the M2 cells. When the M2 cells
were transiently transfected to express aIIbb3 (Fig. 6B), co-
expression with FLNA suppressed PAC-1 binding, a mAb specific
for the activated form of the integrin. Total expression of aIIbb3
in the cells also did not decrease due to the presence FLNA in this
model system. In the same experiment, talin head and migfilin
Figure 4. Effect of migfilin depletion on integrin-dependent functions in HUVECs. (A) Migfilin siRNA causes a .70% reduction in migfilin
protein levels in HUVECs 48 hours after transfection with a migfilin targeting siRNA compared to a control siRNA. Western blot of migfilin is
shown along with actin as a loading control. (B, C) Knockdown of migfilin impairs cell spreading on fibronectin- (15 mg/ml) or fibrinogen- (20 mg/
ml) coated coverslips. Area of at least 100 cells was measured for each ligand and each time-point. (D) Migfilin knockdown impairs VEGF-induced
directed migration of HUVEC across fibronectin and fibrinogen. The upper wells were seeded with HUVECs, resuspended in non-COMPLETE
HUVEC media with 0.1% BSA, and underside of the transwell filters were coated with fibronectin and fibrinogen as in the cell spreading assay. The
lower chamber contained above media and 15 mg/ml (for fibronectin coated filters) or 20 mg/ml (fibrinogen coated filters) of VEGF. Cells were
allowed to migrate for 8 hrs at 37uC. Data are representative of 3 independent experiments. Values are means6 S.E. ** denotes p,0.01 and
* denotes p,0.05.
doi:10.1371/journal.pone.0026355.g004
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obtained when the same experiment was performed in CHO cells
(data not shown).
Filamin, the inhibitor and migfilin, the promoter of
integrin activation
Having shown that migfilin can activate and FLN potently
inhibit multiple integrin classes, we next tested the effects of co-
expression of migfilin and FLNA on integrin activation using M2
cells. Expression of migfilin alone led to enhanced activation of
endogenous b1 integrins in these cells as monitored with HUTS-4
(p,0.05) (Fig. 7A). In this co-expression system using differentially
color-tagged protein constructs, full-length FLNA expression was
low and so we used a vector encoding for a smaller fragment,
FLNA16-24. Expression of this FLNA fragment suppressed
HUTS-4 binding to the cells. When FLNA16-24 and migfilin
were co-expressed in the cells, expression of migfilin or of FLN16-
24 was not altered compared to the single transfectant (Fig. S2).
Migfilin induced .3 fold integrin activation compared to vector
control (p,0.05). Moreover, migfilin expression overcame the
inhibitory effect of FLNA16-24 by inducing significantly higher
(p,0.05) HUTS-4 binding than FLNA16-24 alone (Fig. 7A).
Since migfilin can rescue FLN-induced inhibition of integrin
activation, and the N-terminal region of migfilin interacts with
FLNA/C [34], we examined the effects of N-terminal segment of
migfilinonb1 integrinactivation. Forthese experiments,weused A7
(FLNA
+) cells, which has both FLNA and FLNB isoforms. Upon
transient transfection, the N terminal region of migfilin (residues 1–
85) caused a significant increase in HUTS-4 binding compared to
vector alone (p,0.05) and was significantly different from migfilin
full length (p,0.05). As a test for specificity, we generated a mutant
of this region in which three residues S
11S
12V
13 was mutated to
D
11D
12A
13.Asexpected,themutant N-terminalconstruct(NterMT)
caused significantly less b1 integrin activation (p,0.05) compared to
the WT N-terminal construct (Fig. 7B) and its effect was not
statistically different from that observed with vector alone. Thus,
usingtwoindependentapproaches,cellpermeablesyntheticpeptides
and transient transfection, it was found that the FLN binding region
of migfilin contributes to the capacity of migfilin to promote integrin
activation.
Figure 5. Role of migfilin in b2 integrin dependent function. Empty vector or migfilin were nucleofected into HL60 or dHL60 cells; and, after
24 hours, adhesion of the transfected cells to immobilized iC3b, a ligand for b2 integrins, was assessed as described in Materials and methods. No
difference was observed between vector control and migfilin in HL60 cells (A), but with the dHL60 cells, migfilin transfection resulted in a higher
(p,0.05) adhesion compared to vector alone (B). Data (means 6S.E.) are representative of 3 independent experiments. * denotes p,0.05. The
positive control for this assay was Mn
2+ as in earlier experiments.
doi:10.1371/journal.pone.0026355.g005
Figure 6. FLNA inhibits integrin activation. (A) Full length FLNA or FLNA repeat 21 inhibit b1 integrin activation as monitored by HUTS-4
binding in CHO cells. (B) PAC1 binding is inhibited by full length FLNA in M2 cells transiently over-expressing aIIbb3 integrin (p,0.05). Data are
optimized for surface expression of aIIbb3 integrin as measured by 2G12 antibody. In both cases, talin head and migfilin activated the respective
integrins. Results are representative of 3 independent experiments for HUTS-4 and PAC-1 binding. Values are means6 S.E. ** denotes p,0.01 and
* denotes p,0.05.
doi:10.1371/journal.pone.0026355.g006
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Regulation of integrin activation influences many cellular
processes including adhesion, spreading and migration that occur
in response to different physiological and pathological agonists.
FLN was shown to inhibit integrin mediated CHO cell migration,
and talin, which is essential for integrin activation [40], associated
with integrin only when the FLN-integrin association was
diminished [6]. This competition between FLN and talin is likely
to regulate integrin activation [1] but also could influence talin-
and FLN-dependent outside-in signaling [8]. If FLN is a negative
regulator of integrin activation, some mechanism can be
anticipated to relieve the suppressive effect of FLN by influencing
its release from the b CT. Migfilin seems to be at least one of the
good candidates to perform this task. In our earlier work, we
demonstrated that migfilin binds to FLN repeat 21 at an identical
site as b integrin CT [4]. The higher affinity of migfilin for FLN
compared to the b integrin CT thereby facilitates integrin
activation. However, this competition will not only be governed
by affinity but also by the relative local concentrations of the
competitors and other factors within the microenvironment of the
cell. Accordingly, in the present work, we investigated the role of
FLN in inside-out integrin activation, examined the migfilin levels
in various cell types and determined how the migfilin-FLN-
integrin axis influences integrin function in these cells. The major
findings of our study are: (1) Migfilin is expressed at variable levels
in a wide variety of physiologically relevant cell types. (2) Migfilin
influences activation of three major subfamilies of integrins – b1,
b2 and b3. (3) Migfilin can play a functional role in controlling
integrin-mediated responses in intact cells as migfilin knockdown
suppresses spreading and impairs migration of endothelial cells,
and over-expression enhances adhesion of differentiated HL60
cells to an integrin-dependent ligand, iC3b. (4) FLN inhibits
activation of b1 and b3 integrins. (5) The inhibitory effect of FLN
on integrin activation can be overcome by co-expression with
migfilin. (6) Mechanistically, the Nterminal region of migfilin plays
a dominant role in the integrin activation response.
Although some information on the presence of migfilin mRNA
in platelets and several human tissues has been published [10] our
study reveals the presence of migfilin protein in various naturally
occurring human cells. Migfilin levels in endothelial and
circulating cells varied substantially; with high abundance in
endothelial cells, lower levels in leukocytes and still lower levels in
platelets. Of note, cells which differ substantially in FLN content,
A7 and M2 cells, expressed similar migfilin levels. FLN is also
abundant in platelets where migfilin is expressed at very low levels.
Thus, there is not a direct relationship between migfilin and FLN
levels. Based on western blots and band intensities, endothelial
cells, M2 and A7 cells express predominantly full-length migfilin,
whereas circulating blood cells have higher levels of FBLP-1 or
isoform B, the isoform lacking the third LIM domain.
Migfilin over-expression or import of its FLN binding peptide
overcame the inhibitory effect of FLN and functioned as an
integrin activator. The integrin activating activity of migfilin was
observed with b1 integrins in HUVECs, CHO cells and M2 and
A7 melanoma cells, b2 integrins in neutrophils and granulocytic
cells, and b3 integrins in endothelial cells (BAEC, HUVEC) and
M2 cells expressing exogenous aIIbb3 integrins. Supporting the
role of migfilin in integrin activation, the ability of endothelial cells
to spread or migrate on ligands (fibronectin, fibrinogen) recog-
Figure 7. Migfilin can rescue FLNA-induced inhibition of integrin activation & its N-terminal mediates integrin activation. (A) For
analyzing the role of single proteins on integrin activation, EGFP-migfilin was transfected with empty DsRed vector (the FLN vector) and DsRed-
FLNA16-24 with empty EGFP vector (the migfilin vector) into M2 cells. Empty EGFP and DsRed vectors were co-transfected and used as controls.
HUTS-4 binding of EGFP and DsRed positive cells was used to monitor the activation of the endogenous b1 integrins of the cells by FACS, correcting
for changes in protein expression. While migfilin activates, FLNA16-24 inhibits b1 integrins. Migfilin enhances the activation of the integrin when co-
expressed with FLNA16-24 (p,0.05). (B) The N-terminal (residues 1–85) FLN binding region of migfilin (Nter) or its triple mutant (NterMT) with
reduced FLN binding activity was transfected into A7 cells, and b1 integrin activation monitored by HUTS-4 binding. Both migfilin full length and the
Nter segment of migfilin activated b1 integrins, but the NterMT was significantly less activating than Nter alone (p,0.05). Data are representative of
multiple independent experiments. Values are means6 S.E. * denotes p,0.05.
doi:10.1371/journal.pone.0026355.g007
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reduced by siRNA knockdown in HUVECs. Of note, although we
were able to achieve 70–90% knockdown migfilin in HUVEC, the
same migfilin siRNA preparation reduced migfilin levels minimal-
ly (,20%) in K562 cells stably expressing aIIb3. Migfilin mRNA
in these cells may simply respond differently to the particular
siRNA used. In the same K562 cells, a siRNA to FLNA was very
effective in reducing FLNA levels, and transfection of talin-H into
these cells enhanced integrin activation beyond that induced by
talin H alone; i.e., these data recapitulated the observations in
Fig. 6B where talin-H enhanced activation of the integrin in the
M2 (FLNA
2) cells. b2 integrin function, as monitored by
recognition of iC3b, was also regulated by migfilin. It is well
established that talin and kindlins are essential to the activation of
these integrins in intact cells [41]. Thus, migfilin appears to
facilitate integrin activation driven by talin and kindlin. Unlike
talin and kindlin, migfilin is not known to bind directly to b CT.
Migfilin itself may be targeted to the integrin activation sites by
kindlins [9]. The cumulative impact of these interactions is that
migfilin displaces FLN from the integrin and allows unfettered
access of talin and kindlin to the freed integrin CT to facilitate
integrin activation. However, migfilin also has other binding
partners other than FLN, including VASP [11], CSX/Nx2.5 [13],
kindlin-1, 2 [9,42]; and Src [12], and these interactions may also
play a role in the complex network of integrin activation. Further
studies are required to address these issues which may also
ultimately explain the observation that the activating effect of
migfilin on b1 integrins (,3–5 fold) appears to be greater than that
observed for b2 and b3 integrins (,2 fold).
We did note above that the suppressive effects of migfilin
knockdown in HUVECs were time dependent; i.e., the cells with
migfilin knockdown did ultimately spread and migrate. Thus, the
relationship between integrin activators, talin and kindlin,
suppressors, FLN, and modulators, such as migfilin, must be
delicately and dynamically balanced. In our studies, we assume
that the integrin activation measured by HUTS-4 or PAC-1 as
well as ligand binding represents affinity modulation rather than
avidity modulation consequent to clustering of the integrins [43].
A recent study with PAC-1 suggests that this reagent reports on
avidity modulation [44]. The multiplicity of integrin binding
motifs in FLN [5] would allow it to participate in integrin
clustering and migfilin would still be able to displace FLN and
allow for integrins within clusters to undergo activation.
In this study, we used both human model cell lines and naturally
occurring cells to demonstrate that FLN is a negative regulator of
integrin activation. These observations are consistent with the
publications of Calderwood et al. [6] and Kiema et al [1], which
demonstrated that FLNA competes with talin for binding to the
integrin b7 CT. Based on the involvement of the conserved
TS(T)T motif in FLN binding and the implication of this same
motif in kindlin binding [14,15], the suppression of integrin
activation may reflect the competition of FLN with both integrin
activators.
Finally, the recent study showing that deficiency of migfilin in
mice does not perturb development and homeostasis [45]
deserves special comment. This lack of an overt phenotype is
consistent with the normal development of mice lacking other
zyxin family members [46,47,48]. Thus, the role of migfilin in
integrin activation is not as essential for mouse development as
that of the kindlins and talin, where deficiencies are associated
with severe pathologies [e.g. 49,50,51] including embryonic or
postnatal lethality [52,53]. However, one cannot exclude that
migfilin may be important for human but not mouse develop-
ment. More importantly, integrin activation not only occurs
during development but also in a variety of stress-induced
responses, such as angiogenesis and wound healing, as well as
tumor growth. It is thus possible that migfilin may act as a
‘‘booster’’ that enhances integrin activation. Such enhancement
may not be essential for mouse development but may be critical
for later stage of normal and abnormal cellular and tissue
activities. Keratinocytes derived from the migfilin-deficient mice
did exhibit a slower migration [45], which may reflect a
diminished integrin function. The role of migfilin in vivo may
become apparent if the deficient animals encounter a particular
challenge as had been found for mice deficient in other zyxin
family proteins [54;55]. Based on data developed in our study
responses involving aVb3-mediated endothelial cell migration,
such as angiogenesis or wound closure, and/or aMb2-mediated
leukocyte opsinization of foreign pathogens might be responses
particularly sensitive to migfilin deficiency. Interestingly, despite
the lack of any overt phenotype in an in vivo model, researchers
from the Fa ¨ssler group have also reported that in contrast to
kindlin-2 and FLN, migfilin and VASP levels in focal adhesions
are reduced by inhibition of myosin II [56], thus revealing the
importance of migfilin in focal adhesion dynamics. A recent
structural study by [36] also, shows the potential of migfilin,
besides b7 integrins and GP1ba to regulate FLN inter-repeat
dynamics involved in cytoskeletal rearrangement. Thus, future
studies in the interplay of migfilin, FLN, talin and the kindlins will
help to elucidate the dynamics of the integrin activation-
inhibition cascade.
Supporting Information
Figure S1 Dose-dependent PAC-1 binding induced by
WT and MT migfilin peptides in human platelets. Data
are mean 6S.E and representative of multiple experiments using
platelets from different donors. * denotes p,0.05.
(TIF)
Figure S2 Expression levels of FLN in FLNA16-24 or
FLNA16-24+migfilin transfections are similar in M2 cells
used for the experiment in Fig. 7(A). Depicted are the FLN
expressing cells (DsRed
+) from a population of cells expressing
both green (EGFP vector or migfilin) and red (FLN) constructs.
(TIF)
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